Stock Market & Financial Investment News

News Breaks January 28, 2013 13:37 EDT PFE Earnings Preview: Pfizer near 52-week high ahead of Q4 results Pfizer (PFE) is scheduled to report Q4 earnings before the market open on Tuesday January 29, with a conference call scheduled for 10:00 am ET. Pfizer is a biopharmaceutical company that engages in the discovery, development, manufacture, and sale of medicines for people and animals worldwide... EXPECTATIONS: Analysts are looking for EPS of 44c on revenue of $14.4B, according to First Call. The consensus range for EPS is 43c-47c on revenue of $13.94B-$14.66B... LAST QUARTER: Pfizer reported Q3 EPS of 53c against estimates of 53c on revenue of $14B against estimates of $14.64B. At the time of its Q3 earnings release, the drug giant gave FY12 EPS guidance $2.14-$2.17 on a consensus of $2.21. Note that consensus estimates for FY12 have since been reduced to $2.16... STREET RESEARCH: On December 31, Leerink Swann said it believes Bristol-Myers (BMY) and Pfizer's (PFE) Eliquis was approved with a solid label and is positioned to be the leader for stroke prevention in atrial fibrillation... PRICE ACTION: Pfizer shares are trading close to a 52-week high of $27.30, which was reached on January 24. Shares are up about 8% in the month of January. In early afternoon trading, Pfizer shares are near flat at ~$27. News For PFE From The Last 14 Days Check below for free stories on PFE the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 22, 2013 08:59 EDT PFE On The Fly: Pre-market Movers Subscribe for More Information 08:06 EDT PFE Zoetis comments on Pfizer’s split-off plans for remaining interest Subscribe for More Information 08:04 EDT PFE Pfizer announces plan to split-off remainder of Zoetis Subscribe for More Information 08:02 EDT PFE Pfizer announces plan to split-off remainder of Zoetis Subscribe for More Information May 21, 2013 07:16 EDT PFE Pfizer management to meet with Leerink Subscribe for More Information May 20, 2013 17:04 EDT PFE Pfizer discontinues phase 3 study of inotuzumab ozogamicin Subscribe for More Information May 16, 2013 08:55 EDT PFE BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.